CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
Lotrafilcon B +1 moredevice
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Age 18-35 years
  • ✓Habitual prescription between +5.00 D and -6.00 D
  • ✓Vertex corrected refractive cylinder ≤-0.75 D
  • ✓Best correctable visual acuity 20/25 or better in each eye
Key exclusion· 4
  • ✕Active condition preventing contact lens wear
  • ✕History of eye alignment or binocularity issues
  • ✕Doctor-diagnosed accommodative or binocular vision problems
  • ✕Ocular surface disease or dry eye requiring regular, ongoing treatment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03881670
NCT03881670Phase 4Completed
CompareCT.gov

On-Eye Optical Quality of Lotrafilcon B Lenses Over 12 Hours

Indiana University·interventional·Posted Mar 19, 2019·Updated Mar 10, 2020

In Brief

A Phase 4 clinical trial evaluating Lotrafilcon B and lotrafilcon B with Hydraluxe for Hyperopia and Myopia. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The current study aims to systematically investigate the diurnal variation in the optical quality of soft contact lenses on eye throughout the day. Subject reported quality of vision will also be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperopia, Myopia
CountriesUnited States
CollaboratorsAlcon Research

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedMar 19, 2019
Enrollment StartDec 7, 2018
Primary CompletionFeb 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.3 years ago

Interventions

Lotrafilcon Bdevice

commercially available contact lens

lotrafilcon B with Hydraluxedevice

commercially available contact lens